Drug intelligence / Profile preview

PC-0086

Development stage: Preclinical
Lead developer: Changtai Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

PC-0086 is a small molecule oral solution being developed by Changtai Pharmaceutical (also known as PharmaMax Corp) for the treatment of pediatric arthritis. The drug is part of Changtai's specialized pipeline focusing on improved formulations, particularly for pediatric and respiratory applications. While the specific molecular target has not been publicly disclosed in the company's high-level pipeline summaries, the drug is designed as an oral solution to improve dosing accuracy and patient compliance in the pediatric population suffering from arthritic conditions, such as juvenile idiopathic arthritis.

Beyond the preview

Go deeper on PC-0086.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PC-0086.

Explore the full profile